| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ:AHI) (“AHI” or the “Company”) would like to inform shareholders that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with Qompium NV
AHI will expand Biometric Health Assessment (BHA) with a mobile service for detecting atrial fibrillation and heart rhythm abnormality. • Up to 40% of atrial fibrillation (AF) patients are asymptomatici . • AHI will launch a Mobile Phone-Based AF-Scan for Atrial Fibrillation Assessment. • The application has medical approval in Australia, USA, Singapore, EU, UK, UAE and Saudi Arabia for near clinical. • The global prevalence of atrial fibrillation (AF) is approximately 60 million cases. ii • AF increases the risk of stroke five-fold.iii • AF is a prevalent arrhythmia affecting as many as 1 in 4 people over 40.iv
Posted In: AHI
